Inspire Medical Presents at Wells Fargo, Reiterating Inspire V and 2026 Reimbursement Catalysts

What happened

Inspire Medical Systems presented at the Wells Fargo 2026 MedTech Innovation Spotlight, where management likely reinforced the narrative around the Inspire V product transition and the upcoming Medicare reimbursement uplift. The DeepValue master report rates INSP as a Potential Buy with 3.5 conviction, noting that the stock has derated to a point where improved reimbursement and cost discipline could drive normalized EPS above $2 by 2026. However, the presentation did not introduce material new information; the core thesis remains balanced against GLP-1 competition and DOJ investigation risks. The 2026 reimbursement boost is a key catalyst, but execution on Inspire V adoption and volume growth is critical. The stock currently trades at ~55x trailing EPS with a net cash balance sheet, offering a risk-reward skewed to the upside if GLP-1 headwinds prove contained.

Implication

The presentation confirms management's focus on executing Inspire V adoption and capitalizing on the 2026 Medicare reimbursement uplift that improves per-procedure economics for centers. While GLP-1 competition remains a structural overhang, the current $99 price embeds conservative expectations. For investors, the key implications are two-fold: (1) the 2026 tailwind should support mid-teens revenue growth and margin expansion if volume holds, making the stock attractive below $100; (2) but risks persist—DOJ investigation, GLP-1 adoption, and execution on Inspire V—so sizing should reflect high volatility. Over 6-18 months, successful rollout and stable demand could drive the stock toward the $120 base case, while failure to sustain growth could push it to $70. The presentation did not alter the risk-reward profile.

Thesis delta

No change. The DeepValue thesis already incorporated the 2026 reimbursement catalyst and Inspire V transition as key drivers. The Wells Fargo presentation did not provide incremental data that would shift the base case of 10-13% revenue growth and improving margins. The thesis remains a potential buy with a $120 base case, contingent on GLP-1 headwinds being manageable.